Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide

References

• SiegelRNaishadhamDJemalACancer Statistics, 2012CA Cancer J Clin201262102922237781
   PubMed Web of Science ®Google Scholar
• WhittemoreASCharacteristics relating to ovarian cancer risk: implications for prevention and detectionGynecol Oncol1994553 IIS15S97835800
   PubMed Web of Science ®Google Scholar
• GargPPKerlikowskeKSubakLGradyDHormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysisObstet Gynecol19989234724799721791
   PubMed Web of Science ®Google Scholar
• PurdieDGreenABainCReproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control studyInt J Cancer19956266786847558414
   PubMed Web of Science ®Google Scholar
• RischHAHoweGRPelvic inflammatory disease and the risk of epithelial ovarian cancerCancer Epidemiol Biomarkers Prev1995454474517549798
   PubMed Web of Science ®Google Scholar
• SchildkrautJMSchwinglPJBastosEEvanoffAHughesCCurtinJPEpithelial ovarian cancer risk among women with polycystic ovary syndromeObstet Gynecol1996884 Pt 15545498841217
   PubMed Web of Science ®Google Scholar
• BeralVHermonCPetoROvarian cancer and body size: Individual participant meta-analysis including 25, 157 women with ovarian cancer from 47 epidemiological studiesPLoS Med201294e100120022606070
   PubMed Web of Science ®Google Scholar
• La VecchiaCDecarliANegriEDietary factors and the risk of epithelial ovarian cancerJ Natl Cancer Inst19877946636693116309
   PubMedGoogle Scholar
• GilsingAMJWeijenbergMPGoldbohmRAVan Den BrandtPASchoutenLJConsumption of dietary fat and meat and risk of ovarian cancer in the Netherlands Cohort StudyAm J Clin Nutr2011931118112621068347
   PubMed Web of Science ®Google Scholar
• HunnJRodriguezGCOvarian cancer: etiology, risk factors, and epidemiologyClin Obstet Gynecol201255132322343225
   PubMed Web of Science ®Google Scholar
• MackayHJBradyMFOzaAMPrognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancerInt J Gynecol Cancer201020694595220683400
   PubMed Web of Science ®Google Scholar
• OmuraGABradyMFHomesleyHDLong-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experienceJ Clin Oncol199197113811501904477
   PubMed Web of Science ®Google Scholar
• FaderANRosePGRole of surgery in ovarian carcinomaJ Clin Oncol200725202873288317617518
   PubMed Web of Science ®Google Scholar
• AaboKAdamsMAdnittPChemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trialsBr J Cancer19987811147914879836481
   PubMed Web of Science ®Google Scholar
• OzolsRFBundyBNGreerBEGynecologic Oncology GroupPhase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol200321173194320012860964
   PubMed Web of Science ®Google Scholar
• CraneLMArtsHJvan OostenMThe effect of chemotherapy on expression of folate receptor-alpha in ovarian cancerCell Oncol2012351918
   PubMed Web of Science ®Google Scholar
• LeamonCPLovejoyCDNguyenBPatient selection and targeted treatment in the management of platinum-resistant ovarian cancerPharmgenomics Pers Med20136111312524109193
   PubMedGoogle Scholar
• YapTACardenCPKayeSBBeyond chemotherapy: targeted therapies in ovarian cancerNat Rev Cancer20099316718119238149
   PubMed Web of Science ®Google Scholar
• NaumannRWColemanRLManagement strategies for recurrent platinum-resistant ovarian cancerDrugs201171111397141221812505
   PubMed Web of Science ®Google Scholar
• MarburgerJHIKvammeFEPriorities for Personalized Medicine2008US President’s Council of Advisors on Science and Technology Available from: http://www.whitehouse.gov/files/documents/ostp/PCAST/pcast_report_v2.pdfAccessed December 19, 2013
   Google Scholar
• DrukerBJTalpazMRestaDJEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaN Engl J Med2001344141031103711287972
   PubMed Web of Science ®Google Scholar
• SaltzLBMeropolNJLoehrerPJSrNeedleMNKopitJMayerRJPhase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptorJ Clin Oncol20042271201120814993230
   PubMed Web of Science ®Google Scholar
• CunninghamDHumbletYSienaSCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med2004351433734515269313
   PubMed Web of Science ®Google Scholar
• Van CutsemEPeetersMSienaSOpen-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancerJ Clin Oncol200725131658166417470858
   PubMed Web of Science ®Google Scholar
• SpiegelsteinOEudyJDFinnellRHIdentification of two putative novel folate receptor genes in humans and mouseGene20002581–211712511111049
   PubMed Web of Science ®Google Scholar
• SaikawaYStructural and functional analysis of the human kb cell folate receptor gene P4 promoter: cooperation of three clustered spl-binding sites with initiator region for basal promoter activityBiochemistry19953431995199617632694
   PubMed Web of Science ®Google Scholar
• KamenBAWangMTStreckfussAJPeryeaXAndersonRGWDelivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recyclesJ Biol Chem19882632713602136093417674
   PubMed Web of Science ®Google Scholar
• LeamonCPLowPSDelivery of macromolecules into living cells: a method that exploits folate receptor endocytosisProc Natl Acad Sci U S A19918813557255762062838
   PubMed Web of Science ®Google Scholar
• TurekJJLeamonCPLowPSEndocytosis of folate-protein conjugates: ultrastructural localization in KB cellsJ Cell Sci199310614234308270640
   PubMed Web of Science ®Google Scholar
• WuMFanJGunningWRatnamMClustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolinJ Membr Biol199715921371479307440
   PubMed Web of Science ®Google Scholar
• ShenFRossJFWangXRatnamMIdentification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificityBiochemistry1994335120912158110752
   PubMed Web of Science ®Google Scholar
• WangJGunningWKelleyKMMRatnamMEvidence for segregation of heterologous GPI-anchored proteins into separate lipid rafts within the plasma membraneJ Membr Biol20021891354312202950
   PubMed Web of Science ®Google Scholar
• MaziarzKMMonacoHLShenFRatnamMComplete mapping of divergent amino acids responsible for differential ligand binding of folate receptors alpha and betaJ Biol Chem199927416110861109110196192
   PubMed Web of Science ®Google Scholar
• ShenFZhengXWangJRatnamMIdentification of amino acid residues that determine the differential ligand specificities of folate receptors alpha and betaBiochemistry19973620615761639166787
   PubMed Web of Science ®Google Scholar
• ElwoodPCKaneMAPortilloRMKolhouseJFThe isolation, characterization, and comparison of the membrane-associated and soluble folate-binding proteins from human KB cellsJ Biol Chem19862613315416154232430957
   PubMed Web of Science ®Google Scholar
• AntonyACUtleyCSMarcellPDKolhouseJFIsolation, characterization, and comparison of the solubilized particulate and soluble folate binding proteins from human milkJ Biol Chem19822571710081100896286637
   PubMed Web of Science ®Google Scholar
• YangXYMackinsJYLiQJAntonyACIsolation and characterization of a folate receptor-directed metalloprotease from human placentaJ Biol Chem19962711911493114998626708
   PubMed Web of Science ®Google Scholar
• AntonyACVermaRSUnuneARLaRosaJAIdentification of a Mg2+-dependent protease in human placenta which cleaves hydrophobic folate-binding proteins to hydrophilic formsJ Biol Chem19892644191119142536692
   PubMed Web of Science ®Google Scholar
• LuhrsCASlomianyBLA human membrane-associated folate binding protein is anchored by a glycosyl-phosphatidylinositol tailJ Biol Chem19892643621446214492557328
   PubMed Web of Science ®Google Scholar
• WangJShenFYanWWuMRatnamMProteolysis of the carboxyl-terminal GPI signal independent of GPI modification as a mechanism for selective protein secretionBiochemistry1997364714583145929398177
   PubMed Web of Science ®Google Scholar
• ConeyLRTomassettiACarayannopoulosLCloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding proteinCancer Res19915122612561321840502
   PubMed Web of Science ®Google Scholar
• MiottiSCanevariSMénardSCharacterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificityInt J Cancer19873932973032434438
   PubMed Web of Science ®Google Scholar
• ChenYLChangMCHuangCYSerous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-responseMol Oncol20126336036922265591
   PubMed Web of Science ®Google Scholar
• AntonyACFolate receptorsAnnu Rev Nutr1996165015218839936
   PubMed Web of Science ®Google Scholar
• MiottiSBagnoliMTomassettiAColnaghiMICanevariSInteraction of folate receptor with signaling molecules lyn and G alpha(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1J Cell Sci2000113234935710633085
   PubMed Web of Science ®Google Scholar
• TomassettiAMangiarottiFMazziMThe variant hepatocyte nuclear factor 1 activates the P1 promoter of the human beta folate receptor gene in ovarian carcinomaCancer Res200363369670412566316
   PubMed Web of Science ®Google Scholar
• KelemenLEThe role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?Int J Cancer2006119224325016453285
   PubMed Web of Science ®Google Scholar
• ToffoliGCernigoiCRussoAGalloABagnoliMBoiocchiMOver-expression of folate binding protein in ovarian cancersInt J Cancer19977421931989133455
   PubMed Web of Science ®Google Scholar
• ToffoliGRussoAGalloAExpression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancerInt J Cancer19987921211269583724
   PubMed Web of Science ®Google Scholar
• FisherDEApoptosis in cancer therapy: crossing the thresholdCell19947845395428069905
   PubMed Web of Science ®Google Scholar
• RighettiSCDella TorreGPilottiSA comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinomaCancer Res19965646896938630996
   PubMed Web of Science ®Google Scholar
• Garin-ChesaPCampbellISaigoPELewisJLJrOldLJRettigWJTrophoblast and ovarian cancer antigen LK26: sensitivity and specificity in immunopathology and molecular identification as a folate-binding proteinAm J Pathol199314225575678434649
   PubMed Web of Science ®Google Scholar
• ZacchettiAMartinFLuisonEAntitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancerJ Nucl Med201152121938194622068897
   PubMed Web of Science ®Google Scholar
• KonnerJABell-McGuinnKMSabbatiniPFarletuzumab, a humanized monoclonal antibody against folate receptor α in epithelial ovarian cancer: a phase I studyClin Cancer Res201016215288529520855460
   PubMed Web of Science ®Google Scholar
• ArmstrongDKWhiteAJWeilSCPhillipsMColemanRLFarletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancerGynecol Oncol2013129345245823474348
   PubMed Web of Science ®Google Scholar
• MorphotekA Safety and efficacy study of farletuzumab in subjects with adenocarcinoma of the lung Available from: http://clinicaltrials.gov/show/NCT01218516. NLM identifier: NCT01218516Accessed January 1, 2014
   Google Scholar
• MorphotekAn efficacy and safety study of MORAb-003 in platinum-resistant or refractory relapsed ovarian cancer (FAR-122) Available from: http://clinicaltrials.gov/show/NCT00738699. NLM identifier: NCT00738699Accessed January 1, 2014
   Google Scholar
• TengLXieJTengLLeeRJClinical translation of folate receptor-targeted therapeuticsExpert Opin Drug Deliv20129890190822663189
   PubMed Web of Science ®Google Scholar
• LeamonCPLowPSFolate-mediated targeting: from diagnostics to drug and gene deliveryDrug Discov Today200161445111165172
   PubMed Web of Science ®Google Scholar
• LeamonCPReddyJAFolate-targeted chemotherapyAdv Drug Deliv Rev20045681127114115094211
   PubMed Web of Science ®Google Scholar
• VlahovIRLeamonCPEngineering folate-drug conjugates to target cancer: from chemistry to clinicBioconjug Chem20122371357136922667324
   PubMed Web of Science ®Google Scholar
• DosioFMillaPCattelLEC-145, a folate-targeted vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancersCurr Opin Investig Drugs2010111214241433
   PubMed Web of Science ®Google Scholar
• LeamonCPParkerMAVlahovIRSynthesis and biological evaluation of EC20: a new folate-derived, 99mTc-based radiopharmaceuticalBioconjug Chem20021361200121012440854
   PubMed Web of Science ®Google Scholar
• LeamonCPReddyJAVlahovIRComparative preclinical activity of the folate-targeted vinca alkaloid conjugates EC140 and EC145Int J Cancer200712171585159217551919
   PubMed Web of Science ®Google Scholar
• LiJSausvilleEAKleinPJClinical pharmacokinetics and exposure-toxicity relationship of a folate-vinca alkaloid conjugate EC145 in cancer patientsJ Clin Pharmacol200949121467147619837906
   PubMed Web of Science ®Google Scholar
• LoRussoPMEdelmanMJBeverSLPhase I study of folate conjugate EC145 (vintafolide) in patients with refractory solid tumorsJ Clin Oncol201230324011401623032618
   PubMed Web of Science ®Google Scholar
• SiegelBADehdashtiFMutchDGEvaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical resultsJ Nucl Med200344570070712732670
   PubMed Web of Science ®Google Scholar
• FisherRESiegelBAEdellSLExploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumorsJ Nucl Med200849689990618483093
   PubMed Web of Science ®Google Scholar
• Merck Sharp and Dohme CorpStudy of EC145 in patients with advanced ovarian and endometrial cancers Available from: http://clinicaltrials.gov/show/NCT00507741. NLM identifier: NCT00507741Accessed January 1, 2014
   Google Scholar
• LawrieTABryantACameronAGrayEMorrisonJPegylated liposomal doxorubicin for relapsed epithelial ovarian cancerCochrane Database Syst Rev20137CD00691023835762
   PubMed Web of Science ®Google Scholar
• NaumannRWMorrisRHarbWProtocol EC-FV-02: a phase II study of ec145 in patients with advanced ovarian cancerPresented at the 16th International Meeting of the European Society of Gynaecological OncologyBelgrade, SerbiaOctober 11–14, 2009
   Google Scholar
• SymanowskiJTMaurerAHNaumannRWShahNPMorgensternDMessmanRAUse of 99mTc-EC20 (a folate-targeted imaging agent) to predict response to therapy with EC145 (folate-targeted therapy) in advanced ovarian cancerJ Clin Oncol201028Suppl 15 Abstr 5034
   Web of Science ®Google Scholar
• Merck Sharp and Dohme CorpPlatinum resistant ovarian cancer evaluation of doxil and EC145 combination therapy (PRECEDENT) Available from: http://clinicaltrials.gov/show/NCT00722592. NLM identifier: NCT00722592Accessed January 3, 2014
   Google Scholar
• NaumannRWSymanowskiJTGhamandeSAPRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancerJ Clin Oncol201028Suppl 18LBA5012b
   Web of Science ®Google Scholar
• NaumannRWColemanRLBurgerRAPRECEDENT: a randomized Phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancerJ Clin Oncol201331354400440624127448
   PubMed Web of Science ®Google Scholar
• Merck Sharp and Dohme CorpStudy for women with platinum resistant ovarian cancer evaluating EC145 in combination with doxil® (PROCEED) Available from: http://clinicaltrials.gov/show/NCT01170650. NLM identifier: NCT01170650Accessed January 3, 2014
   Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)Eur J Cancer20094522824719097774
   PubMed Web of Science ®Google Scholar
• NaumannRWGilbertLMillerAMA randomized double-blind phase III trial comparing vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD plus placebo in patients with platinum-resistant ovarian cancer (PROCEED)J Clin Oncol201331TPS5613
   Google Scholar
• Merck Sharp and Dohme CorpSafety and efficacy study of vintafolide and vintafolide plus paclitaxel compared to paclitaxel alone in participants with Triple Negative Breast Cancer (TNBC) (MK-8109-004) Available from: http://clinicaltrials.gov/show/NCT01953536. NLM identifier: NCT01953536Accessed January 3, 2014
   Google Scholar
• Merck Sharp and Dohme CorpA study of MK-8109 (vintafolide) given alone or with chemotherapy in participants with advanced cancers (MK-8109-001) Available from: http://clinicaltrials.gov/show/NCT01688791. NLM identifier: NCT01688791Accessed January 3, 2014
   Google Scholar
• ChongCLogothetisCSavarajNFritscheHGietnerASamuelsMThe correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patientsJ Clin Pharmacol19882887147183216038
   PubMed Web of Science ®Google Scholar
• GaronEBHarbWAPalSEEC-FV-03: a phase II study of EC145 (folate-receptor targeted therapy) in patients with advanced lung cancerJ Thorac Oncol20094Suppl 1S452
   Google Scholar
• MarkertSLassmannSGabrielBAlpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissueAnticancer Res2008286A3567357219189636
   PubMed Web of Science ®Google Scholar
• WibowoASSinghMReederKMStructures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognitionProc Natl Acad Sci U S A201311038151801518823934049
   PubMed Web of Science ®Google Scholar
• WaltersCLArendRCArmstrongDKNaumannRWAlvarezRDFolate and folate receptor alpha antagonists mechanism of action in ovarian cancerGynecol Oncol2013131249349823863359
   PubMed Web of Science ®Google Scholar
• van DamGMThemelisGCraneLMIntraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human resultsNat Med201117101315131921926976
   PubMed Web of Science ®Google Scholar
• ZajchowskiDAKarlanBYShawverLKTreatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomasMol Cancer Ther201211249250222203729
   PubMed Web of Science ®Google Scholar
• VlahovIRSanthapuramHKWangYAn assembly concept for the consecutive introduction of unsymmetrical disulfide bonds: synthesis of a releasable multidrug conjugate of folic acidJ Org Chem200772165968597217602528
   PubMed Web of Science ®Google Scholar